InvestSMART

Telix Pharmaceuticals Limited (ASX: TLX) - Announcements

- Current share price for TLX : $16.730

ASX company news and announcements for Telix Pharmaceuticals Limited (TLX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Telix Pharmaceuticals Limited (TLX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Telix Pharmaceuticals Limited (TLX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Telix Pharmaceuticals Limited (TLX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$5,685 Prof. Frederik Giesel joins Scientific Advisory Board 9 Mar 2020 8:23AM $1.290 $16.730 risen by 1,196.90%
$5,685 Appendix 3Y - Change in Director Interests - M Nelson 4 Mar 2020 12:08PM $1.275 $16.730 risen by 1,212.16%
$5,685 Positive FDA feedback on NDA submission process 25 Feb 2020 8:57AM $1.510 $16.730 risen by 1,007.95%
$5,685 Annual Report for year ended 31 December 2019 24 Feb 2020 10:07AM $1.600 $16.730 risen by 945.63%
$5,685 Appendix 4E - Summary of Results 24 Feb 2020 10:05AM $1.600 $16.730 risen by 945.63%
$5,685 Corporate Governance Statement for year ended 31 Dec 19 24 Feb 2020 10:03AM $1.600 $16.730 risen by 945.63%
$5,685 Appendix 4G - Key to Governance Disclosures 24 Feb 2020 10:02AM $1.600 $16.730 risen by 945.63%
$5,685 European Leadership Changes and Appointment VP Sales 21 Feb 2020 1:34PM $1.615 $16.730 risen by 935.91%
$5,685 App 2A - Quotation of shares issued on exercise of options 13 Feb 2020 2:34PM $1.510 $16.730 risen by 1,007.95%
$5,685 Appendix 3Y - O Buck - exercise of share options 13 Feb 2020 11:34AM $1.500 $16.730 risen by 1,015.33%
$5,685 Appendix 3G - exercise of unlisted share options 13 Feb 2020 11:31AM $1.500 $16.730 risen by 1,015.33%
$5,685 Sales Note to accompany December 2019 quarter Appendix 4C 29 Jan 2020 9:21AM $1.490 $16.730 risen by 1,022.82%
$5,685 Appendix 4C - December 2019 Quarter 29 Jan 2020 9:19AM $1.490 $16.730 risen by 1,022.82%
$5,685 Telix Granted FDA Approval for ZIRCON Renal Cancer Imaging 23 Jan 2020 10:13AM $1.445 $16.730 risen by 1,057.79%
$5,685 Appendix 3G - issue of unlisted share options 16 Jan 2020 8:25AM $1.415 $16.730 risen by 1,082.33%
$5,685 NDA Clinical Briefing Package Submitted to the US FDA 27 Dec 2019 8:25AM $1.610 $16.730 risen by 939.13%
$5,685 Zircon P3 IND submitted to US FDA 24 Dec 2019 8:52AM $1.505 $16.730 risen by 1,011.63%
$5,685 TLX101 for Brain Cancer IPAX-1 Study Update 23 Dec 2019 8:55AM $1.510 $16.730 risen by 1,007.95%
$5,685 Telix and Vic Cancer Centre receive Cancer Australia grant 19 Dec 2019 4:05PM $1.500 $16.730 risen by 1,015.33%
$5,685 Telix and ATONCO Partner for Bladder Cancer 16 Dec 2019 8:37AM $1.560 $16.730 risen by 972.44%
$5,685 Webcast of CEO presentation to Jefferies Conference 25 Nov 2019 9:01AM $1.840 $16.730 risen by 809.24%
$5,685 CEO presentation to Jefferies London Healthcare Conference 21 Nov 2019 8:23AM $1.910 $16.730 risen by 775.92%
$5,685 Change in substantial, dilution of voting due to Placement 15 Nov 2019 8:25AM $1.850 $16.730 risen by 804.32%
$5,685 Change in substantial, dilution of voting due to Placement 15 Nov 2019 8:24AM $1.850 $16.730 risen by 804.32%
$5,685 Ceasing as substantial holder - following release of escrow 15 Nov 2019 8:24AM $1.850 $16.730 risen by 804.32%

751 - 775 of 948 results

Page 31 of 38

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.